Some successful ways of treating other breast cancer subtypes have been discovered, such as endocrine therapy targeting hormone receptors (ER and PR) or therapies targeting HER2, but because of the lack of receptors in triple-negative breast cancer subtype (ER-, PR-, and HER2-negative), these therapies do not benefit TNBC patients. This evidence concerns the gene NR4A1 and breast carcinoma.